3′-Deoxy-3′-18F-Fluorothymidine PET-Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma Patients

被引:34
|
作者
Idema, Albert J. S. [1 ]
Hoffmann, Aswin L. [2 ,3 ]
Boogaarts, Hieronymus D. [1 ]
Troost, Esther G. C. [2 ,3 ]
Wesseling, Pieter [4 ,5 ]
Heerschap, Arend [6 ]
van der Graaf, Winette T. A. [7 ]
Grotenhuis, J. Andre [1 ]
Oyen, Wim J. G. [8 ]
机构
[1] Radboud Univ Nijmegen, Dept Neurosurg, Med Ctr, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Dept Radiat Oncol, Med Ctr, NL-6500 HB Nijmegen, Netherlands
[3] Maastricht Univ, Med Ctr, Dept Radiat Oncol MAASTRO, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands
[4] Radboud Univ Nijmegen, Dept Pathol, Med Ctr, NL-6500 HB Nijmegen, Netherlands
[5] Vrije Univ Amsterdam, Dept Pathol, Med Ctr, Amsterdam, Netherlands
[6] Radboud Univ Nijmegen, Dept Radiol, Med Ctr, NL-6500 HB Nijmegen, Netherlands
[7] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, NL-6500 HB Nijmegen, Netherlands
[8] Radboud Univ Nijmegen, Dept Nucl Med, Med Ctr, NL-6500 HB Nijmegen, Netherlands
关键词
PET/CT; F-18-fluorothymidine; FLT; high-grade glioma; overall survival; POSITRON-EMISSION-TOMOGRAPHY; IMAGING PROLIFERATION; MALIGNANT GLIOMA; F-18-FLT PET; BRAIN-TUMORS; NECK-CANCER; TRIAL; SEGMENTATION; GLIOBLASTOMA; BEVACIZUMAB;
D O I
10.2967/jnumed.112.105544
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
3'-deoxy-3'-F-18-fluorothymidine (F-18-FLT) is a radiopharmaceutical depicting tumor cell proliferation with PET. In malignancies of the lung, breast, head and neck, digestive tract, brain, and other organs, quantitative assessment of F-18-FLT targeting has been shown to correlate with the proliferation marker Ki-67 and with clinical outcome measures such as time to progression and overall survival (OS). The aim of this study was to assess various PET segmentation methods to estimate the proliferative volume (PV) and their prognostic value for OS in patients with suspected high-grade glioma. Methods: Twenty-six consecutive patients underwent preoperative F-18-FLT PET/CT and T1-weighted MRI of the brain after contrast application. The maximum standardized uptake value (SUVmax) of all tumors was calculated, and 3 different segmentation methods for estimating the PV were used: the 50% isocontour of the SUVmax signal for the PV50%, the signal-to-background ratio (SBR) for an adaptive threshold delineation (PVSBR) method, and the iterative background-subtracted relative threshold level (RTL) method to estimate the PVRTL. The prognostic value of the SUVmax and the different PVs for OS were assessed. Results: Twenty-two patients had glioblastoma multiforme, 2 had anaplastic oligodendroglioma, 1 had anaplastic ependymoma, and 1 had anaplastic astrocytoma. The median OS was 397 d (95% confidence interval, 204-577); 19 patients died during the follow-up period. The PVSBR showed a significantly (P = 0.002) better association with OS than did SUVmax, PVRTL, and PV50%. Receiver-operating-characteristic analysis resulted in a threshold volume for the PVSBR of 11.4 cm(3), with a sensitivity and specificity of 70% and 83%, respectively, for the prediction of OS. Kaplan-Meier analyses showed a significant discrimination between short and long OS (P = 0.024, log rank) for this threshold. Conclusion: The PV as determined by F-18-FLT PET is associated with OS in high-grade malignant gliomas. The SBR method yielded the best results to predict short and long OS.
引用
收藏
页码:1904 / 1910
页数:7
相关论文
共 50 条
  • [31] Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3'-Deoxy-3'-18F-Fluorothymidine PET and Diffusion-Weighted MR Imaging
    Schelhaas, Sonja
    Wachsmuth, Lydia
    Viel, Thomas
    Honess, Davina J.
    Heinzmann, Kathrin
    Smith, Donna-Michelle
    Hermann, Sven
    Wagner, Stefan
    Kuhlmann, Michael T.
    Mueller-Tidow, Carsten
    Kopka, Klaus
    Schober, Otmar
    Schaefers, Michael
    Schneider, Richard
    Aboagye, Eric O.
    Griffiths, John
    Faber, Cornelius
    Jacobs, Andreas H.
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (06) : 983 - 988
  • [32] Kinetic Analysis of 3′-Deoxy-3′-18F-Fluorothymidine (18F-FLT) in Head and Neck Cancer Patients Before and Early After Initiation of Chemoradiation Therapy
    Menda, Yusuf
    Ponto, Laura L. Boles
    Dornfeld, Kenneth J.
    Tewson, Timothy J.
    Watkins, G. Leonard
    Schultz, Michael K.
    Sunderland, John J.
    Graham, Michael M.
    Buatti, John M.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (07) : 1028 - 1035
  • [33] Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non-Small Cell Lung Cancer Using 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET
    Kahraman, Deniz
    Scheffler, Matthias
    Zander, Thomas
    Nogova, Lucia
    Lammertsma, Adriaan A.
    Boellaard, Ronald
    Neumaier, Bernd
    Ullrich, Roland T.
    Holstein, Arne
    Dietlein, Markus
    Wolf, Juergen
    Kobe, Carsten
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (12) : 1871 - 1877
  • [34] A Phase II Study of 3′-Deoxy-3′-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688
    Kostakoglu, Lale
    Duan, Fenghai
    Idowu, Michael O.
    Jolles, Paul R.
    Bear, Harry D.
    Muzi, Mark
    Cormack, Jean
    Muzi, John P.
    Pryma, Daniel A.
    Specht, Jennifer M.
    Hovanessian-Larsen, Linda
    Miliziano, John
    Mallett, Sharon
    Shields, Anthony F.
    Mankoff, David A.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (11) : 1681 - 1689
  • [35] In vivo imaging of cell proliferation in meningioma using 3′-deoxy-3′-[18F]fluorothymidine PET/MRI
    Bashir, Asma
    Binderup, Tina
    Vestergaard, Mark Bitsch
    Broholm, Helle
    Marner, Lisbeth
    Ziebell, Morten
    Fugleholm, Kare
    Kjaer, Andreas
    Law, Ian
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (06) : 1496 - 1509
  • [36] Mismatched intratumoral distribution of [18F] fluorodeoxyglucose and 3′-deoxy-3′-[18F] fluorothymidine in patients with lung cancer
    Wang, Xiangcheng
    He, Yulin
    Zhou, Weina
    Bai, Xia
    Wu, Yiwei
    Wang, Xuemei
    Li, Xiao-Feng
    ONCOLOGY LETTERS, 2017, 14 (05) : 5279 - 5284
  • [37] Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients
    Vees, Hansjoerg
    Senthamizhchelvan, Srinivasan
    Miralbell, Raymond
    Weber, Damien C.
    Ratib, Osman
    Zaidi, Habib
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (02) : 182 - 193
  • [38] 3′-Deoxy-3′-18F-Fluorothymidine PET/CT to Guide Therapy with Epidermal Growth Factor Receptor Antagonists and Bcl-xL Inhibitors in Non-Small Cell Lung Cancer
    Zannetti, Antonella
    Iommelli, Francesca
    Speranza, Antonio
    Salvatore, Marco
    Del Vecchio, Silvana
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (03) : 443 - 450
  • [39] Is 3′-deoxy-3′-[18F] fluorothymidine ([18F]-FLT) the next tracer for routine clinical PET after R [18F]-FDG?
    Couturier, O
    Leost, F
    Campone, M
    Carlier, T
    Chatal, JF
    Hustinx, R
    BULLETIN DU CANCER, 2005, 92 (09) : 789 - 798
  • [40] Early Response Assessment to Targeted Therapy Using 3′-deoxy-3′[(18)F]-Fluorothymidine (18F-FLT) PET/CT in Lung Cancer
    Kairemo, Kalevi
    Santos, Elmer B.
    Macapinlac, Homer A.
    Subbiah, Vivek
    DIAGNOSTICS, 2020, 10 (01)